KOREA PHARMA Statistics

Total Valuation

KOREA PHARMA has a market cap or net worth of KRW 170.14 billion. The enterprise value is 158.62 billion.

Market Cap	170.14B
Enterprise Value	158.62B

Important Dates

Earnings Date	n/a
Ex-Dividend Date	Dec 27, 2024

Share Statistics

KOREA PHARMA has 10.91 million shares outstanding. The number of shares has increased by 14.23% in one year.

Current Share Class	10.91M
Shares Outstanding	10.91M
Shares Change (YoY)	+14.23%
Shares Change (QoQ)	-30.01%
Owned by Insiders (%)	63.39%
Owned by Institutions (%)	0.01%
Float	3.99M

Valuation Ratios

The trailing PE ratio is 56.94.

PE Ratio	56.94
Forward PE	n/a
PS Ratio	2.08
PB Ratio	2.38
P/TBV Ratio	2.52
P/FCF Ratio	57.47
P/OCF Ratio	25.74
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 16.28, with an EV/FCF ratio of 53.58.

EV / Earnings	53.06
EV / Sales	1.94
EV / EBITDA	16.28
EV / EBIT	23.19
EV / FCF	53.58

Financial Position

The company has a current ratio of 3.48, with a Debt / Equity ratio of 0.35.

Current Ratio	3.48
Quick Ratio	2.42
Debt / Equity	0.35
Debt / EBITDA	3.08
Debt / FCF	8.46
Interest Coverage	1.77

Financial Efficiency

Return on equity (ROE) is 4.25% and return on invested capital (ROIC) is 3.30%.

Return on Equity (ROE)	4.25%
Return on Assets (ROA)	2.75%
Return on Invested Capital (ROIC)	3.30%
Return on Capital Employed (ROCE)	5.51%
Revenue Per Employee	610.32M
Profits Per Employee	22.31M
Employee Count	134
Asset Turnover	0.69
Inventory Turnover	2.21

Taxes

Income Tax	-11.62M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -17.17% in the last 52 weeks. The beta is 1.17, so KOREA PHARMA's price volatility has been higher than the market average.

Beta (5Y)	1.17
52-Week Price Change	-17.17%
50-Day Moving Average	14,708.80
200-Day Moving Average	15,927.40
Relative Strength Index (RSI)	45.06
Average Volume (20 Days)	72,256

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, KOREA PHARMA had revenue of KRW 81.78 billion and earned 2.99 billion in profits. Earnings per share was 273.96.

Revenue	81.78B
Gross Profit	35.03B
Operating Income	5.24B
Pretax Income	2.98B
Net Income	2.99B
EBITDA	8.14B
EBIT	5.24B
Earnings Per Share (EPS)	273.96

Full Income Statement

Balance Sheet

The company has 36.57 billion in cash and 25.05 billion in debt, giving a net cash position of 11.52 billion or 1,056.27 per share.

Cash & Cash Equivalents	36.57B
Total Debt	25.05B
Net Cash	11.52B
Net Cash Per Share	1,056.27
Equity (Book Value)	71.41B
Book Value Per Share	6,547.44
Working Capital	54.72B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 6.61 billion and capital expenditures -3.65 billion, giving a free cash flow of 2.96 billion.

Operating Cash Flow	6.61B
Capital Expenditures	-3.65B
Free Cash Flow	2.96B
FCF Per Share	271.44

Full Cash Flow Statement

Margins

Gross margin is 42.83%, with operating and profit margins of 6.40% and 3.66%.

Gross Margin	42.83%
Operating Margin	6.40%
Pretax Margin	3.64%
Profit Margin	3.66%
EBITDA Margin	9.95%
EBIT Margin	6.40%
FCF Margin	3.62%

Dividends & Yields

This stock pays an annual dividend of 50.00, which amounts to a dividend yield of 0.34%.

Dividend Per Share	50.00
Dividend Yield	0.34%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	18.25%
Buyback Yield	-14.23%
Shareholder Yield	-13.91%
Earnings Yield	1.76%
FCF Yield	1.74%

Dividend Details

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

KOREA PHARMA has an Altman Z-Score of 4.16 and a Piotroski F-Score of 6.

Altman Z-Score	4.16
Piotroski F-Score	6